je.st
news
Tag: micromet
Rockville Biotech Micromet Sold for $1.16B
2012-01-28 06:58:23| Biotech - Topix.net
Micromet, Inc. the Rockville-based company developing a drug to fight leukemia, agreed to a $1.16 billion merger with California-based Amgen, Inc., the Maryland company announced in a news release on Thursday .
Tags: sold
biotech
116b
micromet
Micromet deal with Amgen could reap $976 million
2011-07-12 02:31:11| Biotech - Topix.net
Micromet said Monday that the collaboration agreement with Amgen is for the research of antibodies against three undisclosed solid tumor targets.
Micromet Announces Definitive Agreement for $25.0 Million Private Placement
2007-06-20 19:23:00| LifeSciencesWorld
[NEWS] BETHESDA, Md., June 20 /PRNewswire-FirstCall/ — Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that it has entered into a definitive agreement with various institutional investors to raise $25.0 million in a private placement of its common stock. Under the terms of the financing, Micromet is expected to sell approximately 9.2 million shares of common …
Tags: private
agreement
million
placement
Micromet Achieves Milestone in BiTE(R) Research Collaboration with MedImmune
2007-04-23 17:30:00| LifeSciencesWorld
[NEWS] CARLSBAD, Calif., April 23 /PRNewswire-FirstCall/ Micromet, Inc. (Nasdaq: MITI) today announced the achievement of a milestone in its research collaboration with MedImmune, Inc. for the development of new BiTE® molecules targeting carcinoembryonal antigen (CEA), a validated tumor- associated antigen frequently expressed on various human carcinomas. Preclinical data recently presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) showed that CEA-BiTE molecules can…
Tags: research
collaboration
milestone
achieves
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
2007-04-20 00:48:44| Biotech - Topix.net
"As a result of our collaboration around this novel technology platform, MedImmune's portfolio of potential cancer treatments has expanded to include several BiTE molecules targeting a range of tumor types" MedImmune, Inc. and Micromet, Inc. today announced that published proof-of-concept data with a new BiTE molecule show that the compound killed tumor cells at dose levels considerably below those required by ... via Freshnews.com
Tags: data
publish
bite
molecule